Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
78.04
+2.45 (3.24%)
Aug 4, 2025, 4:00 PM - Market closed
Elevation Oncology Stock Forecast
Stock Price Forecast
The 16 analysts that cover Elevation Oncology stock have a consensus rating of "Hold" and an average price target of $77.69, which forecasts a -0.45% decrease in the stock price over the next year. The lowest target is $60 and the highest is $107.
Price Target: $77.69 (-0.45%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Elevation Oncology stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Hold | 14 | 14 | 14 | 14 | 14 | 13 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 20 | 19 | 20 | 20 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Initiates $90 | Buy | Initiates | $90 | +15.33% | Aug 1, 2025 |
| BMO Capital | BMO Capital | Sell Maintains $52 → $60 | Sell | Maintains | $52 → $60 | -23.12% | Jul 30, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $88 → $103 | Strong Buy | Maintains | $88 → $103 | +31.98% | Jul 30, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $73 → $79 | Hold | Maintains | $73 → $79 | +1.23% | Jul 30, 2025 |
| UBS | UBS | Hold Maintains $62 → $68 | Hold | Maintains | $62 → $68 | -12.87% | Jul 30, 2025 |
Financial Forecast
Revenue This Year
4.82B
from 4.24B
Increased by 13.53%
Revenue Next Year
5.32B
from 4.82B
Increased by 10.38%
EPS This Year
5.91
from 0.15
Increased by 3,841.42%
EPS Next Year
6.97
from 5.91
Increased by 17.95%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.1B | 6.0B | 7.2B | ||
| Avg | 4.8B | 5.3B | 5.8B | ||
| Low | 4.5B | 4.7B | 5.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21.1% | 24.5% | 35.1% | ||
| Avg | 13.5% | 10.4% | 9.4% | ||
| Low | 6.0% | -1.8% | -1.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.62 | 8.67 | 10.43 | ||
| Avg | 5.91 | 6.97 | 8.76 | ||
| Low | 5.33 | 4.07 | 7.23 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4,310.0% | 46.7% | 49.5% | ||
| Avg | 3,841.4% | 18.0% | 25.6% | ||
| Low | 3,454.1% | -31.2% | 3.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.